Natera’s Signatera test has shown potential in a newly-published survey for guiding treatment decisions after surgery by identifying colorectal cancer recurrence at an average of 8.7 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after surgery. The prospective, multicenter study enrolled 130 patients with…

Digging deeper than previous cancer genomic studies, the PanCancer Initiative has released an analysis of 33 types of cancer across more than 10,000 patients. The new analysis shows that all 33 cancer types, based on their cellular and genetic makeup and independent of their anatomic site of origin, could be…

Global Gene said it will partner with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) to study rare cancers in South Asian and Indian populations. Global Gene, a genomics data platform and applications developer, said it will offer…

MDxHealth and QUT bluebox, the commercialization arm of the Queensland University of Technology (QUT), said today they will partner to develop a liquid biopsy epigenetic assay designed for early detection of oral cancer. The value of the collaboration was not disclosed. The test will evaluate abnormal DNA methylation changes, an…

MDxHealth and Ghent University in Belgium have announced a licensing and collaboration deal to further develop the methylation in situ hybridization (MISH) diagnostic platform for urological cancers. The molecular diagnostic technology developed by the university allows for the direct visualization of cancer-related epigenetic changes in tissue and liquid samples. Under…

Tempus said today it is partnering with breast cancer specialist and research teams at the University of Chicago Medicine and Biological Sciences (UCM) to detect novel patterns that can predict how patients will respond to treatment. The collaboration, whose value was not disclosed, is designed to improve and personalize treatment…

Research conducted at Purdue University by biochemist W. Andy Tao, Ph.D., details that development of a new protein array that can detect certain types of proteins that are indicators or cancer and other diseases. Dr. Tao, reports the development of a new protein array—a high-throughput platform to analyze multiple proteins…

An international team of researchers has uncovered a multitude of new driver mutations in lung cancer cells that may be responsive to genomically targeted and to immune cell therapies. “We have identified several distinct recurrent mutations that are likely to be recognized by the immune system and therefore would be…

Researchers from the University of Chicago reported on the results from a small trial aimed at patients with advanced metastatic urothelial cancer (UC). Many UC patients frequently have somatic mutations and copy number variation in the ERBB gene family, which are structurally related the epidermal growth factor receptor and the…

Raising hopes for a simple, noninvasive, inexpensive, and easily repeatable test for pancreatic cancer, scientists at Barts Cancer Institute, Queen Mary University, have developed a three-protein biomarker panel that can screen urine samples to identify pancreatic cancer when it is still in its early stages. The panel, the scientists say,…

Advancing the work of The Cancer Genome Atlas (TCGA), a large team of researchers from multiple institutions performed a comprehensive analysis of molecular data from thousands of patients representing 12 different types of cancer. The analysis pointed to an alternative system for classifying cancer. Instead of defining cancers according to…

Knowing whether chemotherapy has been successful in treating cancer is always critical, especially in the case of bladder cancer in which treatment failure often leads to radical cystectomy, or bladder removal surgery. Experienced physicians are able to make that determination. Now, a new machine learning tool has been created to…

Adaptimmune’s pivotal SPEARHEAD-1 trial has shown that the T cell receptor therapy afami-cel effectively targets metastatic synovial sarcoma and myxoid round cell liposarcoma, potentially opening the door for other solid tumors to be treated with T cell therapies. “Synovial sarcoma is a rare cancer with historically limited treatment options and…

Having recently finalized its blockbuster acquisition of antibody drug conjugate (ADC) pioneer Seagen, Pfizer is tidying up its oncology house and making a conspicuous shift towards more biologics. The oncology market  is expected to reach $500B by 2030, and Pfizer wants a big piece of it. Especially as the U.S. is making…

Veracyte announced it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) testing capabilities from cell-free DNA (cfDNA) in liquid biopsies. C2i’s MRD solution requires less than a tube of blood (as little as 3–4 mL blood or 1–2…